Mahzi Therapeutics
Advancing precision therapies for rare neurodevelopmental diseases
https://wefunder.com/mahzi.therapeutics
Total raised on Wefunder: 129340
Total investors: 64
Quick facts
- $60M raised from leading VCs: Venrock, HealthCap, Droia Ventures & HBM Partners
- $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
- Leadership from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
- Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
- CEO with 20+ years at Merck and rare disease pioneers Genzyme & Ultragenyx
- Now enrolling patients in first-ever gene therapy clinical trial for Pitt Hopkins Syndrome
- 800+ rare neurogenetic disorders addressable with our approach; targeting a $16B+ market
- $200-$600M peak annual revenue projected per indication in pipeline (not guaranteed)